Every 10-Q that Equillium, Inc. (EQ) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow EQ and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EQ filings page.
Equillium, Inc. is a clinical‑stage biotechnology company developing therapies for severe autoimmune and inflammatory disorders, primarily its novel aryl hydrocarbon receptor modulator EQ504 and preclinical candidate EQ302. For the six months ended June 30, 2026, it reported a net loss of $10.0 million, improved from $14.4 million in 2025, driven largely by lower research and development spending following the wind down of the EQUATOR study.
Cash and cash equivalents were $57.2 million at June 30, 2026, up from $30.3 million at December 31, 2025, reflecting net $34.8 million of proceeds from a March 2026 private placement of common stock and pre‑funded warrants. Total stockholders’ equity increased to $56.0 million and accumulated deficit reached $226.2 million.
Management expects existing cash to fund operations into 2029 and at least 12 months from the filing date. The company plans to initiate a Phase 1 placebo‑controlled proof‑of‑mechanism study of EQ504 in the fourth quarter of 2026, with data anticipated about six months later, and maintains additional potential financing capacity via a $75.0 million at‑the‑market facility and up to $20.0 million of contingent August 2025 private placement proceeds tied to clinical and stock‑price milestones.
Equillium, Inc. reported a net loss of $5.3M for the quarter ended March 31, 2026, narrowing from $8.7M a year earlier as research and development spending declined after winding down prior clinical programs. Operating expenses fell to $5.6M from $8.9M, driven mainly by lower clinical and headcount-related costs.
Cash and cash equivalents increased to $61.3M at March 31, 2026 from $30.3M at year-end 2025, primarily due to a March 2026 private placement that raised gross proceeds of about $35.0M through common stock and a large pre-funded warrant. Management believes this cash can fund operations into 2029, but the company still has an accumulated deficit of $221.5M and has not generated product revenue.
Equillium’s main focus is advancing EQ504, a novel aryl hydrocarbon receptor modulator, with plans to start a Phase 1 proof-of-mechanism study in mid-2026 and target ulcerative colitis and other gastrointestinal diseases. Additional preclinical work continues on EQ302 and a multi-cytokine platform, while significant potential future dilution exists from pre-funded warrants, stock options and an unused at-the-market equity program.
Equillium, Inc. (EQ) reported a Q3 net loss of $4.23 million with $0 revenue, compared with $12.16 million in revenue a year ago tied to a now‑ended Ono arrangement. Operating expenses were $4.58 million versus $12.84 million last year, reflecting a smaller cost base post‑transition.
Cash and cash equivalents were $33.12 million and stockholders’ equity totaled $30.94 million. The company closed an August 2025 private placement for ~$30 million gross (common stock and pre‑funded warrants), and may raise up to an additional ~$20 million upon clinical and price‑based milestones. During Q3, it also sold shares via its ATM facility for ~$0.9 million gross. Shares outstanding were 60,676,837 at September 30, 2025, and 60,893,283 as of November 10, 2025.
The company terminated prior Biocon agreements and is focusing on EQ504, an aryl hydrocarbon receptor modulator, with an intended Phase 1 proof‑of‑mechanism study by mid‑2026. Management indicates existing cash is expected to fund operations through 2027.